EGFR and cancer: Importantly, the occurrence of co-mutations in EGFR itself or other cancer-drivers at diagnosis may potentially impair the efficacy of tyrosine-kinase-inhibitors (TKIs) and partly explain why approximately 10% of TKI-treated NSCLCs are intrinsically resistant [4].